Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.33 USD | +1.65% | +4.11% | -0.99% |
13/05 | Qiagen Receives FDA Clearance for Clinical Use of Respiratory Infection Test | MT |
13/05 | Qiagen Obtains US FDA Clearance for Respiratory Syndromic Testing Panel | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.99% | 9.67B | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Goldman Sachs Upgrades Qiagen to Buy From Neutral, Raises Price Target to $50 From $47